Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
Abstract Atezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to which patients could be overexposed with the standard 1200 mg q3w dosing remains unknown. Here, we monitored atezolizumab peak and troug...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , |
|---|---|
| Formáid: | LEABHAR |
| Foilsithe / Cruthaithe: |
Wiley,
2023-11-01T00:00:00Z.
|
| Ábhair: | |
| Rochtain ar líne: | Connect to this object online. |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Ar líne
Connect to this object online.3rd Floor Main Library
| Gairmuimhir: |
A1234.567 |
|---|---|
| Cóip 1 | Ar fáil |